Pharma major Lupin Limited (Lupin) announced that it has received approval for its Meloxicam Capsules, 5 mg and 10 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Vivlodex® Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc. The product would be manufactured at Lupin's Aurangabad facility, India, and is expected to be launched shortly.
Meloxicam Capsules, 5 mg and 10 mg, are indicated for management of osteoarthritis (OA) pain.
Meloxicam Capsules (RLD: Vivlodex®) had an annual sales of approximately USD 14 million in the U.S. (IQVIA MAT March 2020).
Shares of LUPIN LTD. was last trading in BSE at Rs.872 as compared to the previous close of Rs. 848.95. The total number of shares traded during the day was 172770 in over 5330 trades.
The stock hit an intraday high of Rs. 874 and intraday low of 852.05. The net turnover during the day was Rs. 149864124.